Cowen analyst Ken Cacciatore noted that Allergan (AGN) indicated during its medical aesthetics analyst day this morning that the company is working on a longer-acting toxin. He believes the Allergan pursuit is not a risk for Revance (RVNC), but is actually confirming of the latter company's thesis that there is indeed a viable market for longer-acting toxins. Any weakness in Revance shares should quickly reverse given the company's clinical data and stage of development, contends Cacciatore, who has an Outperform rating and $55 price target on the stock. In morning trading, Revance shares are well off their earlier lows but remain down about 2.5% to $25.30.